CoChat

The DOI matches its Crossref record; 46 of the 48 references it cites were found in a registry or an index; 2 of the 14 sources its claims cite were checked for support.

Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials

Open access

Abstract

BACKGROUND GLP-1 receptor agonists reduce the risk of major adverse cardiovascular events (MACE) and can also have kidney benefits. However, whether GLP-1 receptor agonists improve clinically important kidney outcomes remains uncertain. We aimed to comprehensively assess the effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes by performing a meta-analysis of randomised controlled trials. METHODS For this meta-analysis, we searched MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials for randomised controlled trials that included at least 500 participants with type 2 diabetes, compared a GLP-1 receptor agonist with placebo with at least 12 months of follow-up, and reported a primary clinical kidney or cardiovascular outcome, from database inception to March 26, 2024. Post hoc, we included the SELECT trial (NCT03574597), which enrolled participants with cardiovascular disease and a BMI of 27 kg/m2 or more without diabetes. Study-level summary data were extracted independently by two authors for inclusion in this random-effects analysis. The main kidney outcome was a composite outcome, consisting of kidney failure (kidney replacement therapy or a persistent estimated glomerular filtration rate [eGFR] <15 mL/min per 1·73 m2), a sustained reduction in eGFR by at least 50% or the nearest equivalent, or death from kidney failure. The main cardiovascular outcome was MACE, consisting of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke. This study is registered with PROSPERO, CRD42024528864. FINDINGS Of the 5140 records identified through the literature search, 11 trials, involving 85 373 participants (29 386 female, 55 987 male), were included in the meta-analysis. In participants with type 2 diabetes (67 769), GLP-1 receptor agonists reduced the composite kidney outcome by 18% compared with placebo (hazard ratio [HR] 0·82, 95% CI 0·73-0·93; I2 =26·41%), kidney failure by 16% (HR 0·84, 0·72-0·99; I2 =0%), MACE by 13% (HR 0·87, 0·81-0·93; I2 =49·75%), and all-cause death by 12% (HR 0·88, 0·83-0·93; I2 =0%). The effect on the composite kidney outcome (HR 0·81, 95% CI 0·72-0·92; I2 =23·11%), kidney failure (HR 0·84, 0·72-0·98; I2 =0%), MACE (HR 0·86, 0·80-0·92; I2 =48·9%), and all-cause death (HR 0·87, 0·82-0·91; I2 =0%) was similar when the SELECT trial was included, with no evidence of heterogeneity between this trial and those including participants with type 2 diabetes (pheterogeneity >0·05). There was no difference in the risk of serious adverse events, including acute pancreatitis and severe hypoglycaemia, between the GLP-1 receptor agonist and placebo groups (risk ratio [RR] 0·95, 95% CI 0·90-1·01; I2 =88·5%). However, treatment discontinuation due to adverse events occurred more frequently in the GLP-1 receptor agonist groups (RR 1·51, 95% CI 1·18-1·94; I2 =96·3%). INTERPRETATION We found evidence that GLP-1 receptor agonists significantly reduce clinically important kidney events, kidney failure, and cardiovascular events. FUNDING None.

Overview

CoChat Summary

TL;DR

This meta-analysis of 11 randomized trials and 85,373 participants found that GLP-1 receptor agonists reduced clinically important kidney outcomes, kidney failure, MACE, and all-cause death in people with type 2 diabetes, with consistent effects when the SELECT trial in people without diabetes was included. Benefits were accompanied by no significant increase in key adverse events, though treatment discontinuation due to adverse events was more frequent with GLP-1 receptor agonists.

Key findings

  • In participants with type 2 diabetes, GLP-1 receptor agonists reduced the composite kidney outcome by 18% (HR 0.82, 95% CI 0.73–0.93; high-certainty evidence), kidney failure by 16% (HR 0.84, 95% CI 0.72–0.99; moderate-certainty evidence), MACE by 13% (HR 0.87, 95% CI 0.81–0.93; high-certainty evidence), and all-cause death by 12% (HR 0.88, 95% CI 0.83–0.93; high-certainty evidence).
  • When the SELECT trial was included, effects were similar: composite kidney outcome HR 0.81 (95% CI 0.72–0.92), kidney failure HR 0.84 (95% CI 0.72–0.98), MACE HR 0.86 (95% CI 0.80–0.92), and all-cause death HR 0.87 (95% CI 0.82–0.91), with no evidence of heterogeneity by diabetes status (all p-heterogeneity >0.05).
  • GLP-1 receptor agonists also reduced worsening kidney function (HR 0.79, 95% CI 0.68–0.92 in type 2 diabetes; HR 0.78, 95% CI 0.68–0.91 including SELECT) and hospitalisation for heart failure by 13%, with no significant heterogeneity by diabetes status (p=0.48).
  • There was no statistically significant difference in total serious adverse events (31.7% vs 32.9%; RR 0.95, 95% CI 0.90–1.01), but treatment discontinuation due to adverse events was more frequent with GLP-1 receptor agonists (12.7% vs 9.2%; RR 1.51, 95% CI 1.18–1.94); rates of acute pancreatitis, severe hypoglycaemia, pancreatic cancer, medullary thyroid cancer, and retinopathy were similar.

Methods

  • Systematic review and meta-analysis of aggregate data from randomized controlled trials, reported per PRISMA and prospectively registered (PROSPERO CRD42024528864).
  • MEDLINE, Embase, and Cochrane CENTRAL were searched to 26 March 2024 for trials with at least 500 participants with type 2 diabetes, GLP-1 receptor agonist versus placebo, at least 12 months of follow-up, and a primary clinical kidney or cardiovascular outcome; the SELECT trial was added post hoc. Eleven trials involving 85,373 participants were included (67,769 with type 2 diabetes and 17,604 without diabetes).
  • Random-effects inverse-variance meta-analysis of hazard ratios or log relative risks, with heterogeneity assessed by I², leave-one-out analyses, trial-level subgroup analyses, number needed to treat, and GRADE certainty assessment.

Limitations

  • The paper states that kidney outcome definitions were not uniform across trials; kidney failure event rates were low in all trials except FLOW; and kidney disease outcome was not the primary outcome in all trials except FLOW.
  • The paper states that lack of individual participant-level data prevented subgroup analyses by participant-level baseline characteristics (e.g., presence or type of heart failure), and that SELECT was the only trial enrolling participants without diabetes, limiting subgroup analyses by diabetes status; all included trials were industry-funded.
  • The paper notes high heterogeneity for total serious adverse events (I²=88.5%) and treatment discontinuation due to adverse events (I²=96.3%), so those summary statistics should be interpreted carefully; this is a limitation evident from the reported heterogeneity.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1016/s2213-8587(24)00271-7

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

2 Valid · 1 Not valid · 8 Not checked · 80 Own results and interpretations

44 more claims

Create a free account to see all 91 claims and to verify the 12 references still open.

See all claims — free account
  • It may state two separate claims as one. 22
  • The quote only partly states this claim. 14
  • Probably not a substantial claim. 11

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Show all 48 references

Research works printed but not linked: 3

  1. 2024, Volume 1: chronic kidney disease, Am J Kidney Dis, 83, S1
  2. 2024, Volume 2: end stage renal disease, Am J Kidney Dis, 83, S256
  3. Schünemann, 2023, Chapter 14. Completing ‘Summary of findings’ tables and grading the certainty of the evidence

Cited by

See all 359

Metadata

Authors
Badve, S. V., Bilal, A., Lee, M. M. Y., Sattar, N., Gerstein, H. C., Ruff, C. T., McMurray, J. J. V., Rossing, P., Bakris, G., Mahaffey, K. W., Mann, J. F. E., Colhoun, H. M., Tuttle, K. R., Pratley, R. E., & Perkovic, V.
Affiliations
  • UNSW Sydney (AU)
  • AdventHealth Orlando (US)
  • University of Glasgow (GB)
  • Population Health Research Institute (CA)
  • Brigham and Women's Hospital (US)
  • University of Copenhagen (DK)
  • University of Chicago (US)
  • Stanford Medicine (US)
  • Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
  • Institute of Genetics and Cancer (GB)
  • University of Washington (US)
Corresponding author
Badve, Sunil V
Venue
The Lancet Diabetes & Endocrinology
Publisher
Elsevier BV
Published
2025-01
Volume
13
Issue
1
Pages
15-28
ISSN
2213-8587 (ISSN-L)
OpenAlex
W4404685978
Cited by
359
References
48
Citations by year
2026: 207 · 2025: 151
FWCI
20.98
Type
journal article
Language
en
Open access
Locations
  • The Lancet Diabetes & Endocrinology (publishedVersion)
  • PubMed (publishedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
  • ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
Keywords
GLP-1 receptor agonists, type 2 diabetes, renal failure, major adverse cardiovascular events, cardiovascular disease, estimated glomerular filtration rate, renal replacement therapy, cardiovascular mortality, myocardial infarction, stroke, renal protection, cardioprotection, SELECT trial, placebo comparison, drug safety and efficacy, drug discontinuation
MeSH terms
Glucagon-Like Peptide-1 Receptor Agonists, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Randomized Controlled Trials as Topic, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-04, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-04 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials. https://app.cochat.ai/papers/10.1016/s2213-8587(24)00271-7
The paper
Badve, S. V., Bilal, A., Lee, M. M. Y., Sattar, N., Gerstein, H. C., Ruff, C. T., McMurray, J. J. V., Rossing, P., Bakris, G., Mahaffey, K. W., Mann, J. F. E., Colhoun, H. M., Tuttle, K. R., Pratley, R. E., & Perkovic, V. (2025). Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(24)00271-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.